HealthMap

Medication and Angiogenesis Inhibition in Prostate Conditions

Based on the Acu-Cell Nutrition framework regarding prostate health, addressing abnormal blood vessel growth (angiogenesis) or prostate enlargement typically involves an understanding of hormonal regulation and pharmacological interventions rather than isolated nutritional cures.

Relevant Pharmaceutical Classes

• 5-Alpha-Reductase Inhibitors
• Drugs such as finasteride and dutasteride are commonly prescribed to reduce prostate size.
• They work by blocking the conversion of testosterone to dihydrotestosterone (DHT), which is a primary driver of prostate cell proliferation and associated vascularity.

• Anti-Androgens and Hormone Therapy
• Medications used in more advanced prostate protocols function by suppressing overall androgen activity, which indirectly helps manage the tissue growth and blood supply associated with the condition.

Key Considerations

• Vascular Endothelial Growth Factor (VEGF)
• While specific oncology drugs target VEGF to inhibit angiogenesis directly in tumors, standard benign prostatic hyperplasia (BPH) treatments focus primarily on hormonal shrinkage rather than direct vessel-growth inhibition.
• Nutritional and Mineral Balance
• Dr. Roth's approach emphasizes that pharmacological treatments often deplete essential trace minerals (zinc, selenium) and vitamins, which must be factored into any long-term management of prostate tissue health.